Nephro Trial Files: Plasma-Lyte-148 vs. Standard IV Fluids in Pediatric Kidney Transplants, Dialysate Sodium Lowering, and Prednisolone vs. Levamisole in Relapsing Nephrotic Syndrome
Nephro Trial Files: Plasma-Lyte-148 vs. Standard IV Fluids in Pediatric Kidney Transplants, Dialysate Sodium Lowering, and Prednisolone vs. Levamisole in Relapsing Nephrotic Syndrome
nephrotrialfiles.substack.com
A pragmatic, open-label, randomized controlled trial of Plasma-Lyte-148 versus standard intravenous fluids in children receiving kidney transplants (PLUTO) Hayes WN et al. Kidney International (February 2024) Bottom Line: This is a pragmatic, open-label, randomized controlled trial with a sample size of 137 pediatric kidney transplant recipients. The study compared the effects of Plasma-Lyte-148 and standard perioperative intravenous fluids on acute electrolyte and acid-base abnormalities in the first 72 hours post-transplant. The primary outcome, acute hyponatremia, was experienced by 53% of participants in the Plasma-Lyte-148 group and 58% in the standard fluids group. However, there were fewer changes to fluid prescriptions and a lower incidence of hyperchloremia and acidosis in the Plasma-Lyte-148 group. Serious adverse events were reported in 9% of participants in the Plasma-Lyte-148 group and 7% in the standard fluids group. The study concluded that Plasma-Lyte-148 did not significantly decrease the incidence of acute hyponatremia but had some benefits in terms of fluid prescription changes and electrolyte abnormalities.
Nephro Trial Files: Plasma-Lyte-148 vs. Standard IV Fluids in Pediatric Kidney Transplants, Dialysate Sodium Lowering, and Prednisolone vs. Levamisole in Relapsing Nephrotic Syndrome
Nephro Trial Files: Plasma-Lyte-148 vs…
Nephro Trial Files: Plasma-Lyte-148 vs. Standard IV Fluids in Pediatric Kidney Transplants, Dialysate Sodium Lowering, and Prednisolone vs. Levamisole in Relapsing Nephrotic Syndrome
A pragmatic, open-label, randomized controlled trial of Plasma-Lyte-148 versus standard intravenous fluids in children receiving kidney transplants (PLUTO) Hayes WN et al. Kidney International (February 2024) Bottom Line: This is a pragmatic, open-label, randomized controlled trial with a sample size of 137 pediatric kidney transplant recipients. The study compared the effects of Plasma-Lyte-148 and standard perioperative intravenous fluids on acute electrolyte and acid-base abnormalities in the first 72 hours post-transplant. The primary outcome, acute hyponatremia, was experienced by 53% of participants in the Plasma-Lyte-148 group and 58% in the standard fluids group. However, there were fewer changes to fluid prescriptions and a lower incidence of hyperchloremia and acidosis in the Plasma-Lyte-148 group. Serious adverse events were reported in 9% of participants in the Plasma-Lyte-148 group and 7% in the standard fluids group. The study concluded that Plasma-Lyte-148 did not significantly decrease the incidence of acute hyponatremia but had some benefits in terms of fluid prescription changes and electrolyte abnormalities.